Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
19,023,727
-
Total 13F shares
-
7,657,053
-
Share change
-
+7,656,793
-
Total reported value
-
$197,846,106
-
Put/Call ratio
-
128%
-
Price per share
-
$25.84
-
Number of holders
-
100
-
Value change
-
+$197,839,361
-
Number of buys
-
98
Institutional Holders of NEKTAR THERAPEUTICS - Common Stock, $0.0001 par value (NKTR) as of Q2 2025
As of 30 Jun 2025,
NEKTAR THERAPEUTICS - Common Stock, $0.0001 par value (NKTR) was held by
100 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,657,053 shares.
The largest 10 holders included
VANGUARD GROUP INC, Nantahala Capital Management, LLC, MILLENNIUM MANAGEMENT LLC, AQR CAPITAL MANAGEMENT LLC, ACADIAN ASSET MANAGEMENT LLC, BlackRock, Inc., Balyasny Asset Management L.P., PRIMECAP MANAGEMENT CO/CA/, TCG Crossover Management, LLC, and RENAISSANCE TECHNOLOGIES LLC.
This page lists
100
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.